Advanced search

Mechanisms involved in the development of tolerance to nitrovasodilator

(1991) JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 17(Suppl. 3). p.S304-S308
Author
Organization
Abstract
The identification of endothelium-derived relaxing factor (EDRF) as nitric oxide (NO) has highlighted the clinical importance of NO-containing drugs (nitrovasodilators and molsidomine). The development of tolerance and cross-tolerance is a well-known problem with the classic nitrovasodilators. Although counterregulatory reflex mechanisms might be involved, desensitization of the vascular smooth muscle cells is the best documented mechanism of tolerance. Impaired metabolization of organic nitrates due to deficiency of reduced thiol groups seems to be the major mechanism responsible for this vascular desensitization. Tolerance preventing strategies (nitrate-free periods, administration of N-acetylcysteine, and use of drugs that do not require thiolgroups for activation of guanylate cyclase) are based on this mechanism.
Keywords
CYCLIC GMP, NITRIC OXIDE, NITROVASODILATORS, TOLERANCE, NITRIC-OXIDE, NITROGLYCERIN TOLERANCE, CORONARY-ARTERIES, N-ACETYLCYSTEINE, GLYCERYL TRINITRATE, ORGANIC NITRATES, CYCLIC-GMP LEVELS, CONGESTIVE HEART-FAILURE, ENDOTHELIUM-DEPENDENT RELAXATION, VASCULAR SMOOTH-MUSCLE

Citation

Please use this url to cite or link to this publication:

Chicago
Van de Voorde, Johan. 1991. “Mechanisms Involved in the Development of Tolerance to Nitrovasodilator.” Journal of Cardiovascular Pharmacology 17 (Suppl. 3): S304–S308.
APA
Van de Voorde, J. (1991). Mechanisms involved in the development of tolerance to nitrovasodilator. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 17(Suppl. 3), S304–S308. Presented at the Satellite symposium of the international union of pharmacology : EDRF and EDRF related substances.
Vancouver
1.
Van de Voorde J. Mechanisms involved in the development of tolerance to nitrovasodilator. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1991;17(Suppl. 3):S304–S308.
MLA
Van de Voorde, Johan. “Mechanisms Involved in the Development of Tolerance to Nitrovasodilator.” JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 17.Suppl. 3 (1991): S304–S308. Print.
@article{224803,
  abstract     = {The identification of endothelium-derived relaxing factor (EDRF) as nitric oxide (NO) has highlighted the clinical importance of NO-containing drugs (nitrovasodilators and molsidomine). The development of tolerance and cross-tolerance is a well-known problem with the classic nitrovasodilators. Although counterregulatory reflex mechanisms might be involved, desensitization of the vascular smooth muscle cells is the best documented mechanism of tolerance. Impaired metabolization of organic nitrates due to deficiency of reduced thiol groups seems to be the major mechanism responsible for this vascular desensitization. Tolerance preventing strategies (nitrate-free periods, administration of N-acetylcysteine, and use of drugs that do not require thiolgroups for activation of guanylate cyclase) are based on this mechanism.},
  author       = {Van de Voorde, Johan},
  issn         = {0160-2446},
  journal      = {JOURNAL OF CARDIOVASCULAR PHARMACOLOGY},
  keyword      = {CYCLIC GMP,NITRIC OXIDE,NITROVASODILATORS,TOLERANCE,NITRIC-OXIDE,NITROGLYCERIN TOLERANCE,CORONARY-ARTERIES,N-ACETYLCYSTEINE,GLYCERYL TRINITRATE,ORGANIC NITRATES,CYCLIC-GMP LEVELS,CONGESTIVE HEART-FAILURE,ENDOTHELIUM-DEPENDENT RELAXATION,VASCULAR SMOOTH-MUSCLE},
  language     = {eng},
  location     = {Antwerp, Belgium},
  number       = {Suppl. 3},
  pages        = {S304--S308},
  title        = {Mechanisms involved in the development of tolerance to nitrovasodilator},
  url          = {http://dx.doi.org/10.1097/00005344-199117003-00055},
  volume       = {17},
  year         = {1991},
}

Altmetric
View in Altmetric